Biohaven Common Stock vs Non Currrent Assets Other Analysis

BHVN Stock

USD 38.45 1.37 3.69%

Biohaven Pharmaceutical financial indicator trend analysis is way more than just evaluating Biohaven Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biohaven Pharmaceutical is a good investment. Please check the relationship between Biohaven Pharmaceutical Common Stock and its Non Currrent Assets Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Common Stock vs Non Currrent Assets Other

Common Stock vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biohaven Pharmaceutical Common Stock account and Non Currrent Assets Other. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Biohaven Pharmaceutical's Common Stock and Non Currrent Assets Other is -0.7. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Biohaven Pharmaceutical Holding, assuming nothing else is changed. The correlation between historical values of Biohaven Pharmaceutical's Common Stock and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Biohaven Pharmaceutical Holding are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Common Stock i.e., Biohaven Pharmaceutical's Common Stock and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

-0.7

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Common Stock

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from Biohaven Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biohaven Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

At this time, Biohaven Pharmaceutical's Selling General Administrative is very stable compared to the past year. As of the 17th of May 2024, Enterprise Value is likely to grow to about 3.2 B, though Tax Provision is likely to grow to (1.3 M).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.4M	1.4M	6.9M	7.3M
Cost Of Revenue	91.7M	1.4M	3.4M	3.2M

Reconciled Depreciation Cost Of Revenue

Biohaven Pharmaceutical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Common Stock Shares Outstanding	Other Liab	Net Tangible Assets	Current Deferred Revenue	Other Assets	Net Receivables	Short Term Investments
Total Assets		0.82	0.87	0.81	0.84	-0.38	0.16	0.83	0.66	0.83	-0.4	0.98	0.34	0.69	-0.11	0.53	1.0	0.18	-0.36	0.44	0.61	0.69	-0.88	0.04	-0.58	-0.18
Other Current Liab	0.82		0.99	0.52	0.79	0.03	-0.32	0.62	0.42	0.81	-0.65	0.75	0.42	0.47	0.36	0.63	0.79	0.58	0.12	-0.03	0.63	0.35	-0.7	0.36	-0.64	-0.08
Total Current Liabilities	0.87	0.99		0.55	0.81	-0.05	-0.27	0.73	0.53	0.83	-0.61	0.82	0.47	0.55	0.32	0.67	0.85	0.56	0.06	0.09	0.66	0.41	-0.74	0.27	-0.66	-0.16
Total Stockholder Equity	0.81	0.52	0.55		0.86	-0.37	0.39	0.52	0.26	0.75	-0.39	0.75	-0.15	0.8	-0.32	0.02	0.79	-0.03	-0.6	0.51	0.64	0.82	-0.95	-0.15	-0.64	-0.31
Property Plant And Equipment Net	0.84	0.79	0.81	0.86		-0.07	-0.1	0.63	0.28	0.92	-0.71	0.75	0.05	0.85	0.17	0.26	0.8	0.47	-0.22	0.34	0.86	0.66	-0.97	-0.01	-0.86	-0.49
Net Debt	-0.38	0.03	-0.05	-0.37	-0.07		-0.84	-0.47	-0.62	0.13	-0.42	-0.51	-0.37	-0.38	0.76	-0.32	-0.45	0.67	0.85	-0.65	0.26	-0.72	0.27	0.66	-0.29	-0.05
Retained Earnings	0.16	-0.32	-0.27	0.39	-0.1	-0.84		0.07	0.23	-0.24	0.52	0.25	-0.11	0.14	-0.97	-0.17	0.22	-0.92	-0.9	0.52	-0.37	0.57	-0.15	-0.48	0.39	0.24
Accounts Payable	0.83	0.62	0.73	0.52	0.63	-0.47	0.07		0.9	0.6	-0.14	0.89	0.67	0.72	0.03	0.76	0.84	0.23	-0.25	0.62	0.52	0.56	-0.64	-0.24	-0.47	-0.43
Cash	0.66	0.42	0.53	0.26	0.28	-0.62	0.23	0.9		0.27	0.21	0.78	0.82	0.41	-0.16	0.84	0.71	-0.03	-0.29	0.52	0.11	0.43	-0.33	-0.25	-0.06	-0.12
Non Current Assets Total	0.83	0.81	0.83	0.75	0.92	0.13	-0.24	0.6	0.27		-0.74	0.72	0.0	0.66	0.26	0.24	0.78	0.54	0.0	0.27	0.9	0.43	-0.87	0.26	-0.87	-0.41
Non Currrent Assets Other	-0.4	-0.65	-0.61	-0.39	-0.71	-0.42	0.52	-0.14	0.21	-0.74		-0.25	0.22	-0.41	-0.48	0.01	-0.33	-0.7	-0.22	0.08	-0.69	-0.24	0.59	-0.2	0.68	0.36
Cash And Short Term Investments	0.98	0.75	0.82	0.75	0.75	-0.51	0.25	0.89	0.78	0.72	-0.25		0.47	0.68	-0.18	0.63	0.99	0.09	-0.43	0.5	0.5	0.72	-0.81	-0.07	-0.47	-0.16
Non Current Liabilities Total	0.34	0.42	0.47	-0.15	0.05	-0.37	-0.11	0.67	0.82	0.0	0.22	0.47		0.15	0.21	0.97	0.39	0.2	0.1	0.09	-0.07	0.08	0.0	-0.11	0.07	0.02
Other Current Assets	0.69	0.47	0.55	0.8	0.85	-0.38	0.14	0.72	0.41	0.66	-0.41	0.68	0.15		-0.01	0.26	0.67	0.23	-0.44	0.7	0.74	0.78	-0.87	-0.47	-0.73	-0.74
Other Stockholder Equity	-0.11	0.36	0.32	-0.32	0.17	0.76	-0.97	0.03	-0.16	0.26	-0.48	-0.18	0.21	-0.01		0.27	-0.17	0.94	0.87	-0.46	0.44	-0.5	0.08	0.41	-0.48	-0.33
Total Liab	0.53	0.63	0.67	0.02	0.26	-0.32	-0.17	0.76	0.84	0.24	0.01	0.63	0.97	0.26	0.27		0.56	0.32	0.11	0.1	0.12	0.17	-0.2	0.0	-0.12	-0.01
Total Current Assets	1.0	0.79	0.85	0.79	0.8	-0.45	0.22	0.84	0.71	0.78	-0.33	0.99	0.39	0.67	-0.17	0.56		0.12	-0.41	0.45	0.55	0.71	-0.85	0.0	-0.52	-0.14
Common Stock	0.18	0.58	0.56	-0.03	0.47	0.67	-0.92	0.23	-0.03	0.54	-0.7	0.09	0.2	0.23	0.94	0.32	0.12		0.7	-0.3	0.64	-0.22	-0.23	0.35	-0.66	-0.43
Short Long Term Debt Total	-0.36	0.12	0.06	-0.6	-0.22	0.85	-0.9	-0.25	-0.29	0.0	-0.22	-0.43	0.1	-0.44	0.87	0.11	-0.41	0.7		-0.63	0.15	-0.84	0.43	0.65	-0.17	-0.01
Common Stock Shares Outstanding	0.44	-0.03	0.09	0.51	0.34	-0.65	0.52	0.62	0.52	0.27	0.08	0.5	0.09	0.7	-0.46	0.1	0.45	-0.3	-0.63		0.32	0.65	-0.48	-0.67	-0.23	-0.61
Other Liab	0.61	0.63	0.66	0.64	0.86	0.26	-0.37	0.52	0.11	0.9	-0.69	0.5	-0.07	0.74	0.44	0.12	0.55	0.64	0.15	0.32		0.29	-0.77	0.15	-0.99	-0.69
Net Tangible Assets	0.69	0.35	0.41	0.82	0.66	-0.72	0.57	0.56	0.43	0.43	-0.24	0.72	0.08	0.78	-0.5	0.17	0.71	-0.22	-0.84	0.65	0.29		-0.8	-0.59	-0.27	-0.28
Current Deferred Revenue	-0.88	-0.7	-0.74	-0.95	-0.97	0.27	-0.15	-0.64	-0.33	-0.87	0.59	-0.81	0.0	-0.87	0.08	-0.2	-0.85	-0.23	0.43	-0.48	-0.77	-0.8		0.12	0.76	0.43
Other Assets	0.04	0.36	0.27	-0.15	-0.01	0.66	-0.48	-0.24	-0.25	0.26	-0.2	-0.07	-0.11	-0.47	0.41	0.0	0.0	0.35	0.65	-0.67	0.15	-0.59	0.12		-0.19	0.47
Net Receivables	-0.58	-0.64	-0.66	-0.64	-0.86	-0.29	0.39	-0.47	-0.06	-0.87	0.68	-0.47	0.07	-0.73	-0.48	-0.12	-0.52	-0.66	-0.17	-0.23	-0.99	-0.27	0.76	-0.19		0.66
Short Term Investments	-0.18	-0.08	-0.16	-0.31	-0.49	-0.05	0.24	-0.43	-0.12	-0.41	0.36	-0.16	0.02	-0.74	-0.33	-0.01	-0.14	-0.43	-0.01	-0.61	-0.69	-0.28	0.43	0.47	0.66

Click cells to compare fundamentals

Biohaven Pharmaceutical Account Relationship Matchups

Biohaven Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	344.3M	111.5M	142.1M	661.8M	513.2M	347.2M
Other Current Liab	52.1M	27.1M	37.2M	79.3M	36.5M	38.6M
Total Current Liabilities	66.2M	29.9M	41.9M	90.0M	55.4M	49.1M
Total Stockholder Equity	(7.4M)	16.8M	34.7M	538.8M	428.0M	449.4M
Property Plant And Equipment Net	8.2M	13.6M	18.2M	52.4M	48.6M	51.0M
Net Debt	(316.7M)	185.0M	550.7M	(174.3M)	(218.8M)	(207.9M)
Retained Earnings	(972.4M)	(1.7B)	(2.6B)	(91.1M)	(499.3M)	(524.3M)
Accounts Payable	14.1M	2.8M	4.8M	10.7M	15.6M	10.0M
Cash	316.7M	82.5M	76.1M	204.9M	249.7M	151.5M
Non Current Assets Total	16.0M	21.7M	47.2M	74.8M	70.8M	40.6M
Non Currrent Assets Other	7.8M	1.0M	3.2M	2.6M	2.4M	4.2M
Cash And Short Term Investments	316.7M	82.5M	76.1M	465.3M	383.1M	270.2M
Liabilities And Stockholders Equity	344.3M	111.5M	142.1M	661.8M	513.2M	347.2M
Non Current Liabilities Total	285.5M	4.8M	5.4M	33.0M	29.8M	55.3M
Other Current Assets	11.6M	10K	2.1M	19.3M	45.7M	47.9M
Other Stockholder Equity	83.5M	98.9M	169.7M	13.9M	39.8M	73.8M
Total Liab	351.7M	34.7M	47.4M	123.0M	85.2M	91.0M
Total Current Assets	328.3M	89.8M	94.8M	587.0M	442.4M	306.6M
Common Stock	881.4M	1.2B	1.7B	615.7M	887.5M	970.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:

How To Invest In Biohaven

Details

Is Biohaven Stock a good investment?

Details

What is Biohaven Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Biohaven Stock analysis

When running Biohaven Pharmaceutical's price analysis, check to measure Biohaven Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biohaven Pharmaceutical is operating at the current time. Most of Biohaven Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biohaven Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biohaven Pharmaceutical's price. Additionally, you may evaluate how the addition of Biohaven Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Global Correlations Find global opportunities by holding instruments from different markets
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Share Portfolio Track or share privately all of your investments from the convenience of any device

Is Biohaven Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.90)

Return On Assets

(0.65)

Return On Equity

(1.34)

The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biohaven Common Stock vs Non Currrent Assets Other Analysis

Common Stock vs Non Currrent Assets Other

Common Stock vs Non Currrent Assets Other Correlation Analysis

Correlation Coefficient

Common Stock

Non Currrent Assets Other

Biohaven Pharmaceutical fundamental ratios Correlations

Biohaven Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biohaven Pharmaceutical fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Biohaven Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Liab	+ 0.97	Non Current Liabilities Total
Common Stock	+ 0.94	Other Stockholder Equity

Net Receivables	- 0.99	Other Liab
Other Stockholder Equity	- 0.97	Retained Earnings
Current Deferred Revenue	- 0.97	Property Plant And Equipment Net
Current Deferred Revenue	- 0.95	Total Stockholder Equity
Common Stock	- 0.92	Retained Earnings
Short Long Term Debt Total	- 0.9	Retained Earnings